Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5254—Virus avirulent or attenuated
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
  • A61K2039/552—Veterinary vaccine
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/18011—Paramyxoviridae
  • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
  • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

• the invention is directed to useful methods for providing in ovo protection against turkey rhinotracheitis (TRT) and/or “Swollen Head Syndrome” (SHS) in avian hosts such as turkeys and chickens. More particularly, vaccines against TRT have proven to be both safe and efficacious upon appropriate in ovo administration to avian hosts as described herein.
• TRT is an upper respiratory tract infection of turkeys that is caused by a pneumovirus. It is a highly contagious, acute disease that afflicts turkeys of all ages.
• the clinical symptoms of TRT infection include a marked, frequently frothy nasal discharge, rales, snicking, sneezing, and head shaking. Ocular discharge or swollen infraorbital sinuses may also be observed in infected turkeys.
• TRTV TRT virus
• SHS Swollen Head Syndrome
• the present invention utilizes commercially-available TRT vaccines adapted for the in ovo methods of administration of the present invention.
• Experimental results establish the safety and efficacy of the in ovo administration of these vaccines to turkeys and to chickens using appropriate dosing parameters.
• the methods of the present invention can be utilized to protect an avian host against TRT, and/or TRT or SHS-related respiratory distress by in ovo administration of such vaccines.
• the present invention provides a method for immunizing in ovo avian hosts against TRTV, and thus providing protection against TRT and/or TRT and SHS respiratory distress.
• the vaccines utilized in the methods of the present invention can advantageously be prepared from commercially-available TRT vaccines.
• Especially suitable for use in the present invention is the commercially available Poulvac® TRT vaccine, available from Fort Dodge Animal Health, Fort Dodge, Iowa or Weesp, The Netherlands.
• the commercial formulation of Poulvac® TRT contains attenuated TRTV, strain K, with a titer of not less than 10 3.2 TCID 50 per dose and is not approved or indicated for in ovo administration.
• TCID 50 refers to a 50% tissue culture infectious dose.
• the vaccine is resuspended in a suitable vehicle so as to provide a TCID 50 in the range of about 10 3.2 to about 10 4.5 , and administered in an amount of approximately 0.05 to 0.1 ml per egg, depending upon the avian species being immunized.
• Administration may be by hand, but is more typically and economically administered by using commercially available egg injection equipment such as that available from Embrex, Inc., North Carolina.
• the exact dosage to be administered will depend upon the avian species to which the vaccine is to be delivered, e.g., smaller birds will require smaller doses.
• Administration of the vaccine typically occurs on or before day 24 of incubation (e.g., turkeys), but other in ovo vaccination times are within the scope of the invention, for example, on or before day 18 of incubation (e.g., chickens).
• Avian hosts for which the vaccines and methods of the present invention are intended include chickens, ducks, turkeys, geese, bantams, quail and pigeons.
• Preferred avian species are the commercially important poultry birds such as chickens, ducks and turkeys.
• the vaccine and method of administration result in substantially no decrease in the percentage of eggs that hatch after in ovo vaccination, when compared to a substantially identical control (non-vaccinated) group.
• this decrease is less than about 10%, and more preferably is less than about 5% relative to the percentage that hatch in the control group. Even more desirable is a decrease of less than about 1-2%.
• the vaccine and method of the invention may actually increase the percentage of eggs that hatch, sometimes by as much as about 1-2% or even more.
• the vaccine is both safe and effective for administration to avian species such as chickens and turkeys.
• Fertile turkey eggs for hatching were obtained from parent turkey flocks which were known to be free of TRTV; and which had not been previously vaccinated against TRT. These eggs were randomly assigned to 2 different groups.
• the first group of 76 fertile eggs was administered the vaccine in ovo on day 24 of incubation.
• the first day of incubation is considered day 0.
• Eggs are laid approximately 2-7 days before incubation.
• Poulvac® TRT (batch TR015, expiration date Jun. 24, 1997 containing a titer of 107.5 TCID 50 ) was used to prepare the in ovo vaccine.
• Three vials of the commercial product were each resuspended in 10 ml of sterile saline to give a resulting suspension having a titer of 105.5 TCID 50 of vaccine per 0.1 ml. These contents were well mixed and pooled. The mixed/pooled contents are redesignated as the “IOV” hereinafter in Example 1.
• the in ovo administration used 0.1 ml of the IOV per egg containing a titer of 105.5 TCID 50 , injected into the amniotic fluid of each of the 76 fertile eggs. Thereafter, these eggs were immediately placed into an incubator (without turning) and left to hatch in the isolation pen in which they were housed. These eggs/hatchlings are referred to as the vaccinated birds.
• a second group of 66 fertile eggs were not vaccinated and were left to hatch under similar conditions in a second isolation pen. These eggs/hatchlings are referred to as the negative control birds.
• each bird was examined daily for clinical signs for a period of 21 days.
• the presence of nasal exudate was assessed by squeezing the beak.
• the severity of clinical disease was scored according to Table 2.
• TABLE 2 Clinical Scoring System score experimentally-observed symptoms 0 none 1 clear nasal exudate 2 turbid nasal exudate 3 swollen infraorbital sinuses or frothy eyes and 1 or 2
• Serological analysis was also performed by collecting blood collected from 10 birds within the parent turkey flock 61 ⁇ 2 weeks after the date that the eggs were received. Blood was also collected from the following 4 sets of birds: (a) at an age of 1 day, from 20 negative control birds; (b) at an age of 21 days, from 21 negative control birds; (c) at an age of 1 day, from 20 vaccinated birds; and (d) at an age of 21 days, from 20 vaccinated birds.
• the GM titers for the 1-day old negative control birds and vaccinated birds were almost identical; i.e., respectively, 4.05 and 4.06.
• two birds among the vaccinated birds had positive titers [see titer values of 7.1 and 8.1—each ⁇ 6.0].
• none of the negative control birds had titers ⁇ 6.0.
• the SD for the negative control birds and the vaccinated birds were, respectively, 0.82 and 1.46.
• the 21-day old blood sampling tests also showed clear differences in the experimentally-measured titers.
• the GM decreased to 3.53 and the SD decreased to 0.46.
• the GM increased to 10.53 and the SD increased to 0.85. Accordingly, the vaccinated birds had greatly elevated titers to TRTV.
• Table 4 presents the data supporting this serological testing of the parent turkey flock, the negative control birds, and the vaccinated birds.
• TABLE 4 TRTV Titers Parent Flock Negative Control Birds Vaccinated Birds 61 ⁇ 2 weeks 1-day age 21-day age 1-day age 21-day age 3.7 3.0 3.8 5.6 11.4 5.5 3.0 3.7 3.9 10.4 4.7 4.5 3.8 4.9 9.5 5.9 4.3 3.0 3.4 11.6 7.7 3.0 3.0 4.0 9.3 5.6 4.8 3.4 3.0 9.9 5.4 4.2 3.6 3.0 11.8 3.7 4.7 3.6 3.0 11.1 5.2 3.9 4.2 3.0 11.0 3.0 3.0 4.5 7.1 9.7 4.7 4.3 5.2 11.1 5.0 3.2 3.9 9.1 3.0 3.9 4.4 11.3 4.8 3.0 3.0 10.6 3.3 3.8 8.1 11.5 5.1 3.5 3.3 11.2 4.5 3.0 3.0 10.5 4.1 3.0 3.0 10.0 5.1 3.5 3.0 9.9 3.0 3.3 3.5 9.6 3.0 3.3
• SPF pathogen-free White Leghorn eggs
• 120 SPF eggs were placed in an incubator, and after 18 days of incubation, the eggs were candled. This resulted in 5 non-fertilized eggs being rejected and 115 fertilized eggs being accepted. Of the 115 accepted eggs, 100 were randomly selected for in ovo vaccination. These 100 eggs were divided into three groups as follows:
• Group 1 eggs/hatchlings were tagged for identification with an orange wing mark comprising a number.
• Group 1 consisted of 30 eggs which, as described below, received an in ovo vaccine at a per egg calculated dose of a titer of 105.5 TCID 50 .
• Group 2 eggs/hatchlings were tagged for identification with a green wing mark comprising a number.
• Group 2 consisted of 40 eggs which, as described below, received an in ovo saline solution of equal volume to the vaccine injected to the Group 1 eggs.
• Group 3 eggs/hatchlings were not tagged.
• Group 3 consisted of 30 eggs which did not receive any in ovo administration (either of the vaccine or of the saline solution).
• the chickens of both Groups 1 and 2 were housed in the same animal room in which they hatched. Appropriate conditions (e.g., feed, drinking water, wood shavings as bedding materials, temperatures, relative humidities, etc.) were maintained.
• Appropriate conditions e.g., feed, drinking water, wood shavings as bedding materials, temperatures, relative humidities, etc.
• the time schedule for this experiment was as follows: The first day of incubation of the eggs of Groups 1, 2, and 3 was termed day 0 of incubation. The date of in ovo administration to the eggs of Group 1 and Group 2 of, respectively, a vaccine and a saline solution was day 18 of incubation. The calculated hatching date corresponded to day 21 of incubation. The study was concluded on a post-hatch date equivalent to day 46 of incubation.
• the IOV vaccine was administered in ovo via injection using a commercially-available Inovoject® egg injection machine from Embrex, Inc., North Carolina to the eggs of Group I.
• the egg-injection administration of the IOV was conducted in accordance with standard procedures.
• a commercially-available saline solution, CLEAR-FLEX® INFUSIEVLOESISTOF, from Bieffle Medital SpA, Italy was administered to the eggs of Group 2.
• Table 5 shows the treatment of the eggs within Groups 1, 2, and 3. TABLE 5 Treatment Of Eggs Group # # eggs/group calculated dose per egg 1 30 10 5.5 TCID 50 vaccine 2 40 only saline solution 3 30 no treatment
• Table 6 presents the experimentally-observed hatchability and mortality results for each of Groups 1, 2, and 3. These results established that the in ovo vaccination of the present invention was safe with respect both hatchability and clinical signs of TRT and/or SHS.
• Hatchability/Mortality Results Group 1 (orange wing Group 2 Group 3 mark) (green wing mark) (no wing mark) vaccine saline no treatment Incubated 30 40 30 Vaccinated 30 40 0 Hatched 28 40 30 Percentage of eggs: Vaccinated 100 100 0 Hatched 93.3 100 100 100
• the body weights of the chicks from both Group 1 (vaccine) and Group 2 (saline) were obtained on day 25.
• Mean body weight of the Group 1 chicks was 209 grams with a standard deviation of 22.1.
• the mean body weight was 217 grams with a standard deviation of 24.8.
• the aim of this study was to ascertain whether in ovo vaccination of 18-day old-chicken embryos is efficacious in preventing TRT and/or SHS disease after virulent challenge at 3 or 6 weeks of age.
• in ovo vaccination of susceptible 18-day-old fertile SPF chicken eggs with 10 4.2 TCID 50 is safe while a dose of 10 3.2 TCID 50 is efficacious against clinical disease.
• Fertile eggs for hatching were obtained from a flock of SPF White Leghorn parents purchased from Whickham Laboratories, United Kingdom.
• the in ovo vaccines of the present invention are prepared from this Poulvac® TRT as follows. Three (3) vials of the commercial vaccine containing a titer of 107.5 TCID 50 were each resuspended in 4 ml of sterile water, and well mixed and pooled. Then 0.4 ml was removed and added to 19.6 ml of sterile PBS to give a final dilution equivalent to 200 ml per vial and a resulting suspension containing a titer of 10 4.2 TCID 50 of vaccine per 0.1 ml. This vaccine was further diluted by removing 2 ml and adding it to 18 ml of sterile PBS to give a resulting suspension of 10 3.2 TCID 50 of vaccine per 0.1 ml.
• the challenge virus was prepared as follows. TRTV from the UK strain BUT 8544, isolated by Dr. R. C. Jones at Liverpool University (U.K.), was passaged 23 times in trachea organ culture (hereinafter, “TOC”), once in poults, reisolated, and passaged once more in TOC. The titer of this challenge virus was 10 4.5 TCID 50 per ml.
• Set 1 a first set of 70 fertile eggs
• Set 2 A second set of 70 eggs
• the eggs were immediately placed into an incubator (without turning) and left to hatch in the pen in which they were housed.
• the eggs of Sets 1 and 2 were housed separately in similar isolation pens.
• a third set of 70 fertile eggs did not receive any in ovo administrations (hereinafter, “Set 3”).
• Set 3 is hereinafter referred to as the negative control birds. These eggs were housed in a third isolation pen.
• the challenged birds were experimentally monitored for 14 days, after which they were bled and killed. The observed signs were recorded using the Table 2 Clinical Scoring System as used in Example 1.
• the total daily score of a group of birds was calculated by summarizing the individual scores of each bird on that day. The cumulative score is the sum of the mean daily scores at days 3-8.
• the ⁇ 2 test was used to analyze the data.
• the total clinical signs seen in the 2 vaccinated groups (Sets 1 and 2) from days 3-8 was compared to those seen in the (Set 3) positive controls on the same days for both the 3-week and 6-week challenges. This monitoring established the following results.
• n refers to the number of birds and “SD” refers to the Standard Deviation.
• Example 3 An analysis of the results of Example 3, including the experimentally-obtained measurements, results, and corresponding statistical analysis, indicates that the lower dose of vaccine (10 3.2 TCID 50 TRTV delivered in ovo to susceptible 18-day-old fertile SPF chicken eggs) was efficacious in that it conferred significant protection against challenge with a virulent strain of TRTV at 6 weeks of age. At 3 weeks of age, protection was also observed; however, in light of the number of birds, the experimentally-observed differences in the protection afforded fell just beneath the level of significance. At the increased vaccination dose of 10 4.2 TCID 50 TRTV per egg (an increase on the order of approximately 1 log10), for both the 3-week and the 6-week challenges, significant protection against exposure to a virulent strain of TRTV was observed.
• the aim of this study was to ascertain whether in ovo vaccination of 18-day-old incubated fertile chicken eggs from a parent flock of commercial broilers is efficacious in preventing TRT and/or SHS disease after virulent challenge at 4 or 6 weeks of age.
• in ovo vaccination of susceptible 18-day-old fertile eggs from TRTV-antibody positive parents with 10 3.2 TCID 50 per egg with a vaccine derived from Poulvac® TRT is efficacious against clinical rhinotracheitis disease.
• Fertile eggs for hatching were obtained from a flock of 37-week-old commercial broiler parents which had been previously vaccinated with live TRT vaccine at 10 weeks of age and with killed TRT vaccine at 18 weeks of age. These eggs were obtained from the Mossbank breeder flock, Marshall Agriculture, Whitburn, Scotland.
• a commercially-available TRT vaccine Poulvac® TRT, available from Fort Dodge Animal Health, Fort Dodge, Iowa or Weesp, The Netherlands was used to prepare the in ovo vaccines of the present invention.
• Three vials of this commercial vaccine containing a titer of 107.5 TCID 50 were each resuspended in 5 ml of sterile water, and the contents well mixed and pooled. The vaccine was further diluted in sterile phosphate-buffered saline (PBS) to give a resulting suspension of 10 3.2 TCID 50 of vaccine per 0.1 ml.
• PBS sterile phosphate-buffered saline
• the challenge virus was prepared as follows. TRTV from the UK strain BUT 8544 (see page 12) was passaged 23 times in trachea organ culture (hereinafter, “TOC”), once in poults, reisolated, and passaged once more in TOC. The titer of this challenge virus was 10 4.5 TCID 50 per ml.
• a number (110) of fertile eggs were not vaccinated/inoculated and were left to hatch separately.
• a day after hatching forty birds were housed in a second isolation pen as the negative control birds. Challenged control birds were called positive control birds.
• Hatching was recorded on days 20, 21, 22, and 23 (inoculation day—zero). After hatch, excess birds were humanely killed or used for the collection of blood.
• the hatchability percentages for the non-vaccinated eggs and the vaccinated eggs were, respectively, 89% and 91% which establishes that, with respect to hatchability, vaccination with a titer of 10 3.2 TCID 50 was safe.
• the total daily score of a group of birds was calculated by summarizing the individual scores of each bird on that day. The cumulative score is the sum of the mean daily scores.
• the ⁇ 2 test was used to analyze the data. The total clinical signs seen in the Set 1 vaccinated group was compared to those seen in the Set 2 positive controls on the same days for both the 4-week and 6-week challenges. This monitoring established the following results.
• the vaccinated birds possessed mean antibody titer levels which were statistically significantly higher than those of the negative control birds. From 4 weeks of age, 20% to 22% of the vaccinated birds had positive titers. With respect to the challenged birds, all birds showed seroconversion at 14 days post-challenge. For both the 4-week and the 6-week challenge studies, the mean titers of the vaccinated group were higher than those of the positive control birds and this difference was statistically significant (P ⁇ 0.05).
• Example 4 An analysis of the entirety of Example 4, including the experimentally-obtained measurements, results, and corresponding statistical analysis indicates that in ovo vaccination of maternal-antibody-positive (MA+) commercial broiler eggs at 18 days incubation with a vaccine derived from Poulvac® TRT at a dosage titer of 10 3.2 TCID 50 per egg did not adversely effect hatchability and provided a reliable, efficient, and efficacious method of vaccine administration.
• This vaccination also conferred significant protection against challenge with a virulent strain of TRTV at 6 weeks of age—when the clinical signs seen were significantly reduced. There was a degree of protection at 4-weeks of age—however, even in the nonvaccinated positive control birds the clinical signs seen at this time were not very severe. Accordingly, although present, the protection afforded against a challenge at 4-weeks was not statistically significant.
• Example 4 Prior to the analysis of Experiments 1-4 above, it had been postulated that the presence of maternal antibodies would adversely effect the effectiveness of vaccines. Example 4 nonetheless and surprisingly establishes that in ovo administration of a TRT vaccine at a titer of 10 3.2 TCID 50 per egg was efficacious in reducing clinical TRT disease in chickens that are MA+. Example 4 strengthens and extends the conclusions reached in Example 3 above; namely, that SPF (MA ⁇ ) chickens which were vaccinated in ovo likewise experienced a reduction of clinical disease.
• Poulvac® Marek HVT lyo batch 350129, containing MD virus, strain FC126 (1000 doses per vial).
• Poulvac® IB Primer batch CX02301, containing 105.0 EID50 IB virus, serotypes M41 and D207 (D274 Clone), per dose (1000 doses per vial).
• Poulvac® Bursa Plus batch 62481, containing 103.2 EID50 IBD virus, strain V877, per vial (2000 doses per vial).
• Vaccine batches were stored at 0-8° C., protected from light, until the day of use and were used according to the manufacturer's specifications. After reconstitution, the vaccines were used within two hours. The following vaccine dilutions were prepared.
• Vaccine dilution for vaccination in-ovo group 1 Poulvac® TRT, batch TR02100, Poulvac® Ovoline ND and Bursamune IN OVO were reconstituted and further diluted in Poulvac® Marek diluent, batch C8109.
• the final dilution contained one commercial dose of each vaccine in 0.05 ml.
• Poulvac® Marek HVT lyo was reconstituted and further diluted in Poulvac® Marek diluent, batch C8109. The dilution contained one commercial dose per 0.5 ml.
• Vaccine dilution for coarse spray vaccination group 1 Poulvac® IB Primer was reconstituted and further diluted in 2.2 liters of demineralized water. The dilution contained one commercial dose per 0.5 ml.
• Vaccine dilution for coarse spray vaccination group 2 Poulvac® NDW, batch BL04302, Poulvac® IB Primer, and Poulvac® TRT, batch TR02200, were reconstituted and further diluted in 3 liters of demineralized water. The final dilution contained one commercial dose per 0.5 ml.
• Vaccine dilution for vaccination group 2 against IBD in drinking water Three vials Poulvac® Bursa Plus were reconstituted and further diluted in tap water.
• 6001 Eggs assigned to group 1 were inoculated with 0.05 ml of a dilution containing 1 dose of Poulvac® TRT, Poulvac® Ovoline ND and Bursamune IN OVO per egg after 18 days incubation using an Embrex Inovoject egg injection machine according to the manufacturer's instructions. 6028 Eggs assigned to group 2 were left non-inoculated.
• Inoculated (group 1) and non-inoculated (group 2) eggs were further incubated (without turning) until hatching in the incubators 1 and 4, respectively, located at the test farm of Fort Dodge AHH, Muiden, The Netherlands. After hatching, 4452 (inoculated, group 1) and 5248 (non-inoculated, group 2) chicks were included in the study, respectively. The chicks were group-housed on wood shavings in animal facilities located in the same shed at the test farm of Fort Dodge AHH, Muiden, The Netherlands. Chicks of group 1 were housed in MUL-L and chicks of group 2 in MUL-R. All chicks were fed ad libitum with commercial broiler pellet and had free access to drinking water provided in bell drinkers.
• the vaccination schedule is shown in Table 22.
• chicks of group 1 were vaccinated with Poulvac® IB Primer.
• One commercial dose was administered by coarse spray using a garden sprayer (Gardena) in 0.5 ml per chick.
• chicks of group 2 were vaccinated with Poulvac® TRT, Poulvac® NDW and Poulvac® IB Primer.
• One commercial dose of each vaccine was administered by coarse spray in one volume of 0.5 ml per chick, as in group 1. Before coarse spray vaccination, the chicks were placed in chicken boxes and were left therein until 3 hours post-vaccination.
• Chicks of group 2 were vaccinated with Poulvac® Bursa Plus, one commercial dose per chick in the drinking water, at 2 weeks of age.
• the vaccine was distributed in a quantity of water that was consumed within 2 hours.
• the chicks were deprived of drinking water during 2 hours before the vaccine was administered.
• Antibody titrations to ND, IB, TRT and IBD virus using ELISA methods were done by BC. ELISA antibody titres of 1159 and 834 or above to ND and IB virus, respectively, are regarded positive. Antibody titres to ND (regarded positive at 396 or above) and IB virus were also determined using the IDEXX test kits. Mean titres were calculated using the BC99 software.
• Results Mean antibody titres to ND, IB, IBD and TRT antigens, determined by AHS and BC, are shown in Tables 23 and 24. TABLE 23 Mean antibody titres to ND, IB M41, IB D274, IBD and TRT, determined by AHS.
• Mean FAT titres to MD virus representing the mean serum dilution demonstrating specific fluorescence, are shown in Table 25. Statistically significant higher FAT titres were observed in group 2 at 2, 3, and 4 weeks of age, showing a higher immunological response at younger age of the birds. TABLE 25 Mean FAT titres to MD virus. mean FAT titre to MD Age group no. samples virus one day 1 10 880 2 10 940 2 weeks 1 24 66 2 24 175* 3 weeks 1 24 172 2 24 612* 4 weeks 1 24 369 2 24 823* 5 weeks 1 24 950 2 24 877 6 weeks 1 24 1129 2 24 1267
• a seroresponse to IBD was shown by the BC test at 3 weeks of age, which is one week before it was shown in the IDEXX test.
• the BC ELISA test seems more sensitive to measure antibody titres to ND than the HI method.
• the BC ELISA test showed a more pronounced response to IB virus than the HI method from 3 weeks of age onwards.
• the BC ELISA test kits seems favorable for measuring antibody titre levels to ND, IB, IBD and TRT viral antigens compared to HI tests to ND, IB M41 and IB D274, or IDEXX test kits to IBD or TRT.
• Tables 26 through 35 provide additional antibody titre results.
• HI antibody titres to ND virus determined by AHS. no. chicks with indicated 2log HI titre In- to ND virus sufficient age Group 1 2 3 4 5 6 7 8 9 Serum one day 1 1 5 3 1 2 2 2 2 4 2 weeks 1 6 12 3 1 1 1 2 2 16 6 3 weeks 1 7 7 6 1 2 1 2 2 2 1 1 0 4 weeks 1 1 4 2 1 1 1 5 2 1 3 1 1 9 5 weeks 1 4 3 6 4 7 2 1 7 4 1 2 6 weeks 1 7 7 6 3 1 2 4 4 4 6 4 2 2
• FAT titres to MD virus determined by CVL. FAT titres to MD virus per group at various ages 1 day of age 2 weeks of age 3 weeks of age 4 weeks of age 5 weeks of age 6 weeks of age group group group group group group group group group group 1 2 1 2 1 2 1 2 1 2 1 2 800 ⁇ 1600 100 200 100 400 100 ⁇ 1600 800 200 800 800 400 800 50 400 neg. 400 200 800 800 50 ⁇ 1600 800 ⁇ 1600 800 50 200 100 200 100 200 400 ⁇ 1600 800 800 800 neg.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Virology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Pulmonology (AREA)
• Communicable Diseases (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=22954857

Family Applications (2)

Family Applications After (1)

Country Status (25)

Families Citing this family (1)

Citations (8)

Family Cites Families (6)

• 2001
  • 2001-11-09 AR ARP010105251A patent/AR031405A1/es not_active Application Discontinuation
  • 2001-11-13 CN CNB018221092A patent/CN100379452C/zh not_active Expired - Lifetime
  • 2001-11-13 US US10/054,288 patent/US20030054016A1/en not_active Abandoned
  • 2001-11-13 AU AU2002243426A patent/AU2002243426B2/en not_active Expired
  • 2001-11-13 AU AU4342602A patent/AU4342602A/xx active Pending
  • 2001-11-13 NZ NZ526556A patent/NZ526556A/en not_active IP Right Cessation
  • 2001-11-13 PT PT01989322T patent/PT1345658E/pt unknown
  • 2001-11-13 KR KR10-2003-7006830A patent/KR20030055314A/ko not_active Application Discontinuation
  • 2001-11-13 YU YU38503A patent/YU38503A/sh unknown
  • 2001-11-13 HU HU0302343A patent/HUP0302343A2/hu unknown
  • 2001-11-13 AT AT01989322T patent/ATE361120T1/de not_active IP Right Cessation
  • 2001-11-13 JP JP2002547528A patent/JP2004536780A/ja active Pending
  • 2001-11-13 WO PCT/US2001/051207 patent/WO2002045745A2/en active IP Right Grant
  • 2001-11-13 MX MXPA03004432A patent/MXPA03004432A/es not_active Application Discontinuation
  • 2001-11-13 ES ES01989322T patent/ES2284717T3/es not_active Expired - Lifetime
  • 2001-11-13 BR BR0115507-5A patent/BR0115507A/pt not_active IP Right Cessation
  • 2001-11-13 PL PL01365848A patent/PL365848A1/xx not_active Application Discontinuation
  • 2001-11-13 DK DK01989322T patent/DK1345658T3/da active
  • 2001-11-13 EP EP01989322A patent/EP1345658B1/en not_active Revoked
  • 2001-11-13 CZ CZ20031419A patent/CZ20031419A3/cs unknown
  • 2001-11-13 DE DE60128264T patent/DE60128264T2/de not_active Revoked
• 2003
  • 2003-05-19 BG BG107826A patent/BG107826A/bg unknown
  • 2003-06-19 ZA ZA2003/04762A patent/ZA200304762B/en unknown
  • 2003-06-20 HR HR20030508A patent/HRP20030508A2/hr not_active Application Discontinuation
  • 2003-11-14 HK HK03108313A patent/HK1055914A1/xx not_active IP Right Cessation
• 2005
  • 2005-10-17 US US11/251,692 patent/US7348012B2/en not_active Expired - Lifetime
• 2007
  • 2007-07-05 CY CY20071100897T patent/CY1106707T1/el unknown

Patent Citations (9)

Also Published As

Similar Documents

Legal Events